Hui Xue, MD
Nephrology · San Diego, CANPI 1255508834
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,478 of the $1,813 with a category attached, or 81.6%. Boehringer Ingelheim International GmbH accounts for 77.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $1,404 and has fallen 72.0% since, to $393 in 2024.
Across 10 payments — averaging $181.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Novartis$374
- Fresenius USA Marketing, Inc.$34
Across 63 payments — averaging $25,807 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.2M
- Boehringer Ingelheim International GmbH$251K
- Boehringer Ingelheim Pharma GmbH & Co.kg$104K
- AstraZeneca$72K
What the payments were for
- Travel & lodging$1,47882%
- Food & beverage$33418%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 6 | $1,404 |
| Novartis | 2 | $374 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$1,265
How this compares
$1,813 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 93 | $45,755 |
| Sevelamer Carbonate | 70 | $14,710 |
| Nifedipine ErNifedipine | 80 | $3,531 |
| Calcitriol | 163 | $3,465 |
| Potassium Chloride | 44 | $1,815 |
| Cinacalcet Hcl | 30 | $1,362 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,266 |
| Valganciclovir Hcl | 23 | $1,006 |
| Allopurinol | 70 | $830 |
| Losartan Potassium | 53 | $765 |
| Furosemide | 55 | $763 |
| Amiloride Hcl | 15 | $716 |
| Amlodipine Besylate | 58 | $711 |
| Lisinopril | 63 | $700 |
| Prednisone | 39 | $585 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Diego
- Ravindra MehtaSan Diego$184K
- Ambarish AthavaleSan Diego$83K
- Juan QuevedoSan Diego$53K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.